Detection of molecular probes.

Some neurological diseases – Alzheimer’s and Parkinson’s disease, for example – are not clinically diagnosed until a threshold of damage has been surpassed. Nevertheless, molecular biomarkers indicative of early disease are present long before clinical expression of neurological deficits.

In many cases, pharmaceutical interventions have the highest likelihood of altering disease trajectory when they occur early in the disease process. Identifying biomarkers by molecular imaging therefore shows great promise in the fight against neurological disease.

MSOT can be used to accurately determine the spatial biodistribution of probes in the mouse brain through an intact skin and skull. In combination with specific probes, this provides the capacity to study molecular features of neurological disease in vivo.

Probe distribution in brain

Image left: Greyscale background is an optoacoustic image taken at 860 nm. Green overlay represents multispectrally resolved probe. Abbreviations: D3V, dorsal third ventricle; SSS, superior sagittal sinus; LV, lateral ventricle; 3V, third ventricle.

Image right: Corresponding cryosection with yellow overlay showing the fluorescence of the fluorescent dye injected into the ventricles of the brain, with an excellent correlation between the in vivo MSOT measurement and the fluorescence image ex vivo.

Lozano N, Al-Jamal WT, Taruttis A, Beziere N, Burton NC, Van den Bossche J, Mazza M, Herzog E, Ntziachristos V, Kostarelos K, Liposome-gold Nanorod Hybrids for High-resolution Visualization Deep in Tissues, J Am Chem Soc, 2012 Aug 15;134(32):13256-8.

  • Lozano L et al.,
    Liposome-Gold Nanorod Hybrids for High-Resolution Visualization Deep in Tissues,
    J Am Chem Soc. 2012, 134 (32), pp 13256–13258. DOI: 10.1021/ja304499q.
Page layout: 0
Page level: 4